# The Human Medicines (Amendments Relating to Naloxone and Transfers of Functions) Regulations 2024, Regulation 3: Amendments to regulation 8


In regulation 8 (general interpretation), in paragraph (1), at the appropriate places insert—
““local naloxone provider” is to be construed in accordance with regulation 237A(3);”;
““naloxone product” means a medicinal product that contains naloxone or a salt, ester or stereoisomeric form of naloxone;”;
““provider of probation services”—
(a) in England and Wales, has the same meaning as in Part 1 of the Offender Management Act 2007 (new arrangements for the provision of probation services); and
(b) in Northern Ireland, means the Probation Board for Northern Ireland;”;
““provider of youth justice services” means—
(a) in England and Wales, a provider, other than a local authority, of the services specified in section 38(4) of the Crime and Disorder Act 1998 (local provision of youth justice services);
(b) in Scotland, a provider, other than a local authority, of the services in Scotland in respect of a child that most closely correspond to the services specified in section 38(4) of the Crime and Disorder Act 1998, and for these purposes “child” has the meaning given in section 199 of the Children’s Hearings (Scotland) Act 2011 (meaning of “child”); and
(c) in Northern Ireland, a body or other person with which or whom the Department of Justice has made arrangements for the provision of juvenile justice centres pursuant to Article 51(2) of the Criminal Justice (Children) (Northern Ireland) Order 1998 (juvenile justice centres);”.

---
Source: https://www.legislation.gov.uk/uksi/2024/1125/regulation/3 (the official version)
Page: https://openlegislation.uk/human-medicines-amendments-relating-to-naloxone-and-transfers-of-functions-regulations-2024/regulation-3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

